blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP4373499

EP4373499 - PROMOTING IMMUNE SURVEILLANCE AGAINST CANCER CELLS [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  27.04.2024
Database last updated on 02.08.2024
FormerThe international publication has been made
Status updated on  27.01.2023
Most recent event   Tooltip27.04.2024Publication in section I.1 EP Bulletinpublished on 29.05.2024  [2024/22]
27.04.2024Request for examination filedpublished on 29.05.2024  [2024/22]
Applicant(s)For all designated states
Mayo Foundation for Medical Education and Research
200 First Street S.W.
Rochester, Minnesota 55905 / US
[2024/22]
Inventor(s)01 / VAN DEURSEN, Jan M.A.
Rochester, Minnesota 55902-3421 / US
02 / LI, Hu
Rochester, Minnesota 55902-1546 / US
03 / STURMLECHNER, Ines
Rochester, Minnesota 55901 / US
04 / DAVID, Nathaniel Eames
San Francisco, California 94108 / US
 [2024/22]
Representative(s)Fish & Richardson P.C.
Highlight Business Towers
Mies-van-der-Rohe-Straße 8
80807 München / DE
[2024/22]
Application number, filing date22846828.621.07.2022
[2024/22]
WO2022US73986
Priority number, dateUS202163224177P21.07.2021         Original published format: US 202163224177 P
[2024/22]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2023004377
Date:26.01.2023
Language:EN
[2023/04]
Type: A1 Application with search report 
No.:EP4373499
Date:29.05.2024
Language:EN
The application published by WIPO in one of the EPO official languages on 26.01.2023 takes the place of the publication of the European patent application.
[2024/22]
Search report(s)International search report - published on:US26.01.2023
ClassificationIPC:A61K35/13, C07K16/24, G01N33/574, C07K16/28
[2024/22]
CPC:
A61K38/195 (EP); A61K31/519 (EP); A61K31/52 (EP);
A61K39/395 (EP); A61K47/6811 (EP); A61K47/6851 (EP);
C07K16/24 (EP); C07K16/2815 (EP); A61K2039/505 (EP);
C07K2317/70 (EP); C07K2317/73 (EP); C07K2317/76 (EP);
G01N33/5047 (EP); G01N33/505 (EP); G01N33/5055 (EP);
G01N33/5067 (EP) (-)
C-Set:
A61K39/395, A61K2300/00 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2024/22]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:FÖRDERUNG DER IMMUNÜBERWACHUNG GEGEN KREBSZELLEN[2024/22]
English:PROMOTING IMMUNE SURVEILLANCE AGAINST CANCER CELLS[2024/22]
French:PROMOTION DE LA SURVEILLANCE IMMUNITAIRE CONTRE DES CELLULES CANCÉREUSES[2024/22]
Entry into regional phase19.02.2024National basic fee paid 
19.02.2024Search fee paid 
19.02.2024Designation fee(s) paid 
19.02.2024Examination fee paid 
Examination procedure19.02.2024Amendment by applicant (claims and/or description)
19.02.2024Examination requested  [2024/22]
Fees paidRenewal fee
19.02.2024Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[YA]US9850306  (BEDI ATUL [US], et al) [Y] 1-2, 4-5, 19-20 * ; column 13, line 66; column 27, line 25-26; column 31, lines 14-15 & 16-17 & 18-19; column 42, lines 4-5 & lines 10-12; * [A] 3, 6;
 [YA]  - Hara T., Tanegashima K., "Pleiotropic functions of the CXC-type chemokine CXCL14 in mammals", Journal of Biochemistry, Oxford University Press, GB, GB , (20120501), vol. 151, no. 5, doi:10.1093/jb/mvs030, ISSN 0021-924X, pages 469 - 476, XP093028027 [Y] 1-2, 4-5, 19-20 [A] 3, 6

DOI:   http://dx.doi.org/10.1093/jb/mvs030
 [Y]  - FOUCHER, ED et al., "IL -34 Induces the Differentiation of Human Monocytes into Immunosuppressive Macrophages. Antagonistic Effects of GM-CSF and IFNc", PLOS ONE, (20130208), vol. 8, no. 2, doi:10.1371/journal.pone.0056045, pages 1 - 10, XP055213470 [Y] 19-20

DOI:   http://dx.doi.org/10.1371/journal.pone.0056045
 [A]  - Alves Eric, Taifour Shahama, Dolcetti Riccardo, Chee Jonathan, Nowak Anna K., Gaudieri Silvana, Blancafort Pilar, "Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing", Molecular therapy- methods & clinical development, Nature Publishing Group, GB, GB , (20210601), vol. 21, doi:10.1016/j.omtm.2021.04.009, ISSN 2329-0501, pages 592 - 606, XP093028025 [A] 3, 6

DOI:   http://dx.doi.org/10.1016/j.omtm.2021.04.009
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.